{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T21:47:07Z","timestamp":1649195227162},"reference-count":35,"publisher":"Akademiai Kiado Zrt.","issue":"45","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Orvosi Hetilap"],"published-print":{"date-parts":[[2014,11]]},"abstract":"<jats:p>Circulating markers of neuroendocrine tumours are useful tools in the diagnosis of these tumours. Laboratory tests for general biomarkers have acceptable sensitivity for the recognition of neuroendocrine tumours as these biologically active proteins are typically synthesized by all types of neuroendocrine cells. Measurement of chromogranin A is widely used not only in the diagnosis of neuroendocrine tumours but it may predict the prognosis of the diseases and the effect of the antitumor therapy. It is also a useful tool for the detection of residual tumours. Neurendocrine tumours represent a heterogeneous group of tumours with the ability to secrete several hormones and, therefore, measurement of these hormones can also serve as neuroendocrine cell type-specific markers in routine clinical practice. In this review the authors summarize the significance of tumour markers in the diagnosis of neuroendocrine tumours as well as in the management and follow-up of patients with this disease. Orv. Hetil., 2014, 155(45), 1775\u20131782.<\/jats:p>","DOI":"10.1556\/oh.2014.30035","type":"journal-article","created":{"date-parts":[[2014,11,2]],"date-time":"2014-11-02T01:01:32Z","timestamp":1414890092000},"page":"1775-1782","source":"Crossref","is-referenced-by-count":1,"title":["Significance of biochemical markers in the diagnosis of neuroendocrine tumours and in the follow-up of patients"],"prefix":"10.1556","volume":"155","author":[{"given":"Judit","family":"T\u0151ke","sequence":"first","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar II. Belgy\u00f3gy\u00e1szati Klinika Budapest"},{"name":"Magyar Tudom\u00e1nyos Akad\u00e9mia-Semmelweis Egyetem \u201eLend\u00fclet\u201d \u00d6r\u00f6kletes Endokrin Daganatok Kutat\u00f3csoport Budapest"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e1bor","family":"Czirj\u00e1k","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar \u00c9lettani Int\u00e9zet Budapest"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikl\u00f3s","family":"T\u00f3th","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar II. Belgy\u00f3gy\u00e1szati Klinika Budapest"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K\u00e1roly","family":"R\u00e1cz","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar II. Belgy\u00f3gy\u00e1szati Klinika Budapest"},{"name":"Magyar Tudom\u00e1nyos Akad\u00e9mia-Semmelweis Egyetem Molekul\u00e1ris Medicina Kutat\u00f3csoport Budapest"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Attila","family":"Pat\u00f3cs","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar Laborat\u00f3riumi Medicina Int\u00e9zet Budapest Szentkir\u00e1lyi u. 46. 1088"},{"name":"Magyar Tudom\u00e1nyos Akad\u00e9mia-Semmelweis Egyetem \u201eLend\u00fclet\u201d \u00d6r\u00f6kletes Endokrin Daganatok Kutat\u00f3csoport Budapest"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"<i>Hauso, O., Gustafsson, B. I., Kidd, M., et al.:<\/i> Neuroendocrine tumor epidemiology. Contrasting Norway and North America. Cancer, 2008, <i>113<\/i>(10), 2655\u20132664.","DOI":"10.1002\/cncr.23883"},{"key":"2","doi-asserted-by":"crossref","unstructured":"<i>Oberg, K., Hellman, P., Ferolla, P., et al.:<\/i> Neuroendocrine bronchial and thymic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 2012, <i>23<\/i> (Suppl. 7), vii120\u2013vii123.","DOI":"10.1093\/annonc\/mds267"},{"key":"3","doi-asserted-by":"crossref","unstructured":"<i>Lawrence, B., Gustafsson, B. I., Chan, A., et al.:<\/i> The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol. Metab. Clin. North Am., 2011, <i>40<\/i>(1), 1\u201318.","DOI":"10.1016\/j.ecl.2010.12.005"},{"key":"4","doi-asserted-by":"crossref","unstructured":"<i>Vinik, A. I., Woltering, E. A., Warner, R. R., et al.:<\/i> NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas, 2010, <i>39<\/i>(6), 713\u2013734.","DOI":"10.1097\/MPA.0b013e3181ebaffd"},{"key":"5","unstructured":"<i>T\u00f3th, M.:<\/i> A neuroendokrin tumorok kezel\u00e9s\u00e9nek lehet\u0151s\u00e9gei. Lege Artis Med., 2013, <i>23<\/i>(10\u201311), 503\u2013516. [Hungarian]"},{"key":"6","doi-asserted-by":"crossref","unstructured":"<i>Modlin, I. M., Gustafsson, B. I., Moss, S. F., et al.:<\/i> Chromogranin A \u2013 biological function and clinical utility in neuro endocrine tumor disease. Ann. Surg. Oncol., 2010, <i>17<\/i>(9), 2427\u20132443.","DOI":"10.1245\/s10434-010-1006-3"},{"key":"7","doi-asserted-by":"crossref","unstructured":"<i>Giusti, M., Sidoti, M., Augeri, C., et al.:<\/i> Effect of short-term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man. Eur. J. Endocrinol., 2004, <i>150<\/i>(3), 299\u2013303.","DOI":"10.1530\/eje.0.1500299"},{"key":"8","doi-asserted-by":"crossref","unstructured":"<i>Stridsberg, M., Eriksson, B., Oberg, K., et al.:<\/i> A comparison between three commercial kits for chromogranin A measurements. J. Endocrinol., 2003, <i>177<\/i>(2), 337\u2013341.","DOI":"10.1677\/joe.0.1770337"},{"key":"9","doi-asserted-by":"crossref","unstructured":"<i>Bajetta, E., Ferrari, L., Martinetti, A., et al.:<\/i> Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer, 1999, <i>86<\/i>(5), 858\u2013865.","DOI":"10.1002\/(SICI)1097-0142(19990901)86:5<858::AID-CNCR23>3.0.CO;2-8"},{"key":"10","doi-asserted-by":"crossref","unstructured":"<i>Stokkel, M. P., Rietbergen, D. D., Korse, C. M., et al.:<\/i> Somatostatin receptor scintigraphy and chromogranin A assay in staging and follow-up of patients with well-differentiated neuroendocrine tumors. Nucl. Med. Commun., 2011, <i>32<\/i>(8), 731\u2013737.","DOI":"10.1097\/MNM.0b013e328347a895"},{"key":"11","doi-asserted-by":"crossref","unstructured":"<i>Campana, D., Nori, F., Piscitelli, L., et al.:<\/i> Chromogranin A: is it a useful marker of neuroendocrine tumors? J. Clin. Oncol., 2007, <i>25<\/i>(15), 1967\u20131973.","DOI":"10.1200\/JCO.2006.10.1535"},{"key":"12","doi-asserted-by":"crossref","unstructured":"<i>Jensen, E. H., Kvols, L., McLoughlin, J. M., et al.:<\/i> Biomarkers predict outcomes following cytoreductive surgery for hepatic metastases from functional carcinoid tumors. Ann. Surg. Oncol., 2007, <i>14<\/i>(2), 780\u2013785.","DOI":"10.1245\/s10434-006-9148-z"},{"key":"13","doi-asserted-by":"crossref","unstructured":"<i>Massironi, S., Conte, D., Sciola, V., et al.:<\/i> Plasma chromogranin A response to octreotide test: prognostic value for clinical outcome in endocrine digestive tumors. Am. J. Gastroenterol., 2010, <i>105<\/i>(9), 2072\u20132078.","DOI":"10.1038\/ajg.2010.154"},{"key":"14","doi-asserted-by":"crossref","unstructured":"<i>Rossi, R., Garcia-Hernandez, J., Martin, N., et al.:<\/i> PTH-093 chromogranin-A: Can it predict radiological progression in neuroendocrine tumours? Gut, 2014, <i>63(Suppl. 1)<\/i>, A251.","DOI":"10.1136\/gutjnl-2014-307263.539"},{"key":"15","doi-asserted-by":"crossref","unstructured":"<i>Welin, S., Stridsberg, M., Cunningham, J., et al.:<\/i> Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors. Neuroendocrinology, 2009, <i>89<\/i>(3), 302\u2013307.","DOI":"10.1159\/000179900"},{"key":"16","doi-asserted-by":"crossref","unstructured":"<i>Rustagi, S., Warner, R. R., Divino, C. M.:<\/i> Serum pancreastatin: the next predictive neuroendocrine tumor marker. J. Surg. Oncol., 2013, <i>108<\/i>(2), 126\u2013128.","DOI":"10.1002\/jso.23359"},{"key":"17","doi-asserted-by":"crossref","unstructured":"<i>McGrath-Linden, S. J., Johnston, C. F., O\u2019Connor, D. T., et al.:<\/i> Pancreastatin-like immunoreactivity in human carcinoid disease. Regul. Pept., 1991, <i>33<\/i>(1), 55\u201370.","DOI":"10.1016\/0167-0115(91)90015-9"},{"key":"18","doi-asserted-by":"crossref","unstructured":"<i>O\u2019Dorisio, T. M., Krutzik, S. R., Woltering, E. A., et al.:<\/i> Development of a highly sensitive and specific carboxy-terminal human pancreastatin assay to monitor neuroendocrine tumor behavior. Pancreas, 2010, <i>39<\/i>(5), 611\u2013616.","DOI":"10.1097\/01.mpa.0000363937.59530.70"},{"key":"19","doi-asserted-by":"crossref","unstructured":"<i>Stridsberg, M., Eriksson, B., Fellstr\u00f6m, B., et al.:<\/i> Measurements of chromogranin B can serve as a complement to chromogranin A. Regul. Pept., 2007, <i>139<\/i>(1\u20133), 80\u201383.","DOI":"10.1016\/j.regpep.2006.10.008"},{"key":"20","doi-asserted-by":"crossref","unstructured":"<i>Portela-Gomes, G. M., Grimelius, L., Wilander, E., et al.:<\/i> Granins and granin-related peptides in neuroendocrine tumours. Regul. Pept., 2010, <i>165<\/i>(1), 12\u201320.","DOI":"10.1016\/j.regpep.2010.02.011"},{"key":"21","doi-asserted-by":"crossref","unstructured":"<i>Conlon, J. M.:<\/i> Granin-derived peptides as diagnostic and prognostic markers for endocrine tumors. Regul. Pept., 2010, <i>165<\/i>(1), 5\u201311.","DOI":"10.1016\/j.regpep.2009.11.013"},{"key":"22","doi-asserted-by":"crossref","unstructured":"<i>Vinik, A. I., Silva, M. P., Woltering, E. A., et al.:<\/i> Biochemical testing for neuroendocrine tumors. Pancreas, 2009, <i>38<\/i>(8), 876\u2013889.","DOI":"10.1097\/MPA.0b013e3181bc0e77"},{"key":"23","doi-asserted-by":"crossref","unstructured":"<i>Yao, J. C., Pavel, M., Phan, A. T., et al.:<\/i> Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J. Clin. Endocrinol. Metab., 2011, <i>96<\/i>(12), 3741\u20133749.","DOI":"10.1210\/jc.2011-0666"},{"key":"24","doi-asserted-by":"crossref","unstructured":"<i>Kanakis, G., Kaltsas, G.:<\/i> Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs). Best Pract. Res. Clin. Gastroenterol., 2012, <i>26<\/i>(6), 791\u2013802.","DOI":"10.1016\/j.bpg.2012.12.006"},{"key":"25","doi-asserted-by":"crossref","unstructured":"<i>Tam\u00e1si, L., M\u00fcller, V.:<\/i> Symptoms and diagnostics of lung neuroendocrine tumors. [A t\u00fcd\u0151 neuroendokrin daganatainak t\u00fcnetei \u00e9s diagnosztik\u00e1ja.] Orv. Hetil., 2011, <i>152<\/i>(10), 366\u2013370. [Hungarian]","DOI":"10.1556\/OH.2011.29041"},{"key":"26","doi-asserted-by":"crossref","unstructured":"<i>Ardill, J. E., O\u2019Dorisio, T. M.:<\/i> Circulating biomarkers in neuroendocrine tumors of the enteropancreatic tract: application to diagnosis, monitoring disease, and as prognostic indicators. Endocrinol. Metab. Clin. North Am., 2010, <i>39<\/i>(4), 777\u2013790.","DOI":"10.1016\/j.ecl.2010.09.001"},{"key":"27","doi-asserted-by":"crossref","unstructured":"<i>O\u2019Toole, D., Salazar, R., Falconi, M., et al.:<\/i> Rare functioning pancreatic endocrine tumors. Neuroendocrinology, 2006, <i>84<\/i>(3), 189\u2013195.","DOI":"10.1159\/000098011"},{"key":"28","doi-asserted-by":"crossref","unstructured":"<i>Kaltsas, G. A., Besser, G. M., Grossman, A. B.:<\/i> The diagnosis and medical management of advanced neuroendocrine tumors. Endocr. Rev., 2004, <i>25<\/i>(3), 458\u2013511.","DOI":"10.1210\/er.2003-0014"},{"key":"29","doi-asserted-by":"crossref","unstructured":"<i>Strosberg, J.:<\/i> Neuroendocrine tumours of the small intestine. Best Pract. Res. Clin. Gastroenterol., 2012, <i>26<\/i>(6), 755\u2013773.","DOI":"10.1016\/j.bpg.2012.12.002"},{"key":"30","doi-asserted-by":"crossref","unstructured":"<i>Jiao, Y., Shi, C., Edil, B. H., et al.:<\/i> DAXX\/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science, 2011, <i>331<\/i>(6021), 1199\u20131203.","DOI":"10.1126\/science.1200609"},{"key":"31","doi-asserted-by":"crossref","unstructured":"<i>Leja, J., Essaghir, A., Essand, M., et al.:<\/i> Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas. Mod. Pathol., 2009, <i>22<\/i>(2), 261\u2013272.","DOI":"10.1038\/modpathol.2008.174"},{"key":"32","doi-asserted-by":"crossref","unstructured":"<i>Darmanis, S., Cui, T., Drobin, K., et al.:<\/i> Identification of candidate serum proteins for classifying well-differentiated small intestinal neuroendocrine tumors. PLoS One, 2013, <i>8<\/i>(11), e81712.","DOI":"10.1371\/journal.pone.0081712"},{"key":"33","doi-asserted-by":"crossref","unstructured":"<i>Panzuto, F., Severi, C., Cannizzaro, R., et al.:<\/i> Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors. J. Endocrinol. Invest., 2004, <i>27<\/i>(1), 6\u201311.","DOI":"10.1007\/BF03350903"},{"key":"34","doi-asserted-by":"crossref","unstructured":"<i>Service, F. J., Natt, N.:<\/i> The prolonged fast. J. Clin. Endocrinol. Metab., 2000, <i>85<\/i>(11), 3973\u20133974.","DOI":"10.1210\/jcem.85.11.6934"},{"key":"35","doi-asserted-by":"crossref","unstructured":"<i>Berna, M. J., Hoffmann, K. M., Long, S. H., et al.:<\/i> Serum gastrin in Zollinger-Ellison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. Evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features. Medicine (Baltimore), 2006, <i>85<\/i>(6), 331\u2013364.","DOI":"10.1097\/MD.0b013e31802b518c"}],"container-title":["Orvosi Hetilap"],"original-title":[],"language":"hu","link":[{"URL":"https:\/\/www.akademiai.com\/doi\/pdf\/10.1556\/OH.2014.30035","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T09:56:19Z","timestamp":1590141379000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/doi\/10.1556\/oh.2014.30035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":35,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["10.1556\/OH.2014.30035"],"URL":"https:\/\/doi.org\/10.1556\/oh.2014.30035","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11]]}}}